02.27.2017 | Investors

Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan

DUBLIN, Feb. 27, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Lisa DeFrancesco, Vice President of Investor Relations, has decided to leave Allergan to pursue other professional opportunities.

Allergan plc logo

"After nearly 8 years of leading the Investor Relations function during the transformation of our Company from Watson, a U.S. focused generics company, to Actavis, a leading global generics company to Allergan, a leading branded growth pharma company, I have decided that now is the right time to pursue other career opportunities," said DeFrancesco. "I am proud of our accomplishments and appreciate the support Allergan has received from investors and analysts."

"Lisa has done an outstanding job of leading the Investor Relations function through the company's incredible transformation from a small, U.S. focused generics company into the large cap global biopharmaceutical leader that it is today. Her contributions have been instrumental to Allergan's success, and I wish her well in her future endeavors," said Brent Saunders, Chairman and Chief Executive Officer of Allergan.

"Lisa has been a terrific leader helping to convey the Company's growth and value story to investors and analysts. I have enjoyed working with Lisa and wish her all the best and continued success in the future," said Tessa Hilado, Chief Financial Officer of Allergan.

The Company has started an executive search to fill the position. Ms. DeFrancesco will continue in her current role until a successor is named to ensure a smooth transition.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.



Lisa DeFrancesco
(862) 261-7152

Mark Marmur
(862) 261-7558


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lisa-defrancesco-vice-president-of-investor-relations-to-leave-allergan-300413691.html

SOURCE Allergan plc

Media Contacts
Amy Rose
Global Corporate Media Relations
+1 (862) 289 3072
Lisa Brown
Global Corporate Media Relations
+1 (862) 261 7320
Fran DeSena
U.S. Product Media Relations
+1 (862) 261 8820
Mark Marmur
International Communications & Public Relations
+44 7725 758677

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Christine Chiou
Investor Relations
+1 (862) 261-7396